# Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers

Source: https://onco.cc/key-papers/paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019/  
OnCo record `paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Where the immune cells sit matters: triple-negative tumours with killer T cells inside the tumour did well, tumours with no T cells and fibrotic B7-H4-rich stroma did badly, and a third group kept T cells trapped in the stroma with PD-L1 on stromal cells.

## Summary

Spatial resolution of immune cells was integrated with laser-capture microdissection expression profiles of tumour and stroma. Immunoreactive TNBCs had tumoural granzyme B-positive CD8 T cells, a type 1 interferon signature and elevated IDO and PD-L1, with good outcome. An immune-cold microenvironment lacking tumoural CD8 cells was defined by high B7-H4, fibrotic stroma signatures and poor outcome. A distinct poor-outcome immunomodulatory microenvironment showed stromal restriction of CD8 cells, stromal PD-L1 and cholesterol biosynthesis signatures. Metasignatures stratified TNBC outcome and suggested targets.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Journal: Journal of Clinical Investigation
- Year: 2019
- DOI: 10.1172/JCI96313
- Authors: Gruosso T, Gigoux M, Manem VSK, et al.
- Findings: Three spatial immune classes: immunoreactive (good outcome), immune-cold with B7-H4 and fibrosis (poor), stroma-restricted with stromal PD-L1 (poor).; Metasignatures stratify outcome and nominate IDO, PD-L1 and B7-H4 as class-specific targets.
- What it means: It explains why a PD-L1 score alone predicts imperfectly: PD-L1 on stromal cells with excluded T cells is a poor-outcome pattern, and B7-H4 marks the cold tumours now being targeted by antibody-drug conjugates.
- Caveats: Discovery cohort of modest size; classes were defined retrospectively.; Spatial patterns need standardised digital pathology to be used clinically.

## Sources

- Gruosso et al., J Clin Invest 2019: spatially distinct immune microenvironments stratify TNBC: https://doi.org/10.1172/JCI96313
- PubMed: https://pubmed.ncbi.nlm.nih.gov/30753167/

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Digital pathology & AI](https://onco.cc/technologies/digital-pathology-ai/)
- targets: [B7-H4 (VTCN1)](https://onco.cc/targets/b7h4/), [IDO1](https://onco.cc/targets/ido1/), [PD-L1](https://onco.cc/targets/pdl1/)
- pathways: [Cold tumours: immune deserts and exclusion](https://onco.cc/pathways/immune-desert-exclusion/), [Tumour microenvironment (TME)](https://onco.cc/pathways/tumor-microenvironment/)
- terms: [Tumour-infiltrating lymphocytes (TILs)](https://onco.cc/terms/tils/)
- journals: [Journal of Clinical Investigation](https://onco.cc/journals/jci/)

---
JSON: https://onco.cc/api/v1/entities/paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019.json